Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Destiny Pharma. LSE:DEST London Ordinary Share GB00BDHSP575 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  -1.00p -1.48% 66.50p 3,992 15:43:19
Bid Price Offer Price High Price Low Price Open Price
65.00p 68.00p 67.50p 66.50p 67.50p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -3.21 -8.40 29.0

Destiny Pharma. (DEST) Latest News

More Destiny Pharma. News
Destiny Pharma. Takeover Rumours

Destiny Pharma. (DEST) Share Charts

1 Year Destiny Pharma. Chart

1 Year Destiny Pharma. Chart

1 Month Destiny Pharma. Chart

1 Month Destiny Pharma. Chart

Intraday Destiny Pharma. Chart

Intraday Destiny Pharma. Chart

Destiny Pharma. (DEST) Discussions and Chat

Destiny Pharma. Forums and Chat

Date Time Title Posts
25/10/201821:08Destiny Pharma plc32

Add a New Thread

Destiny Pharma. (DEST) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Destiny Pharma. trades in real-time

Destiny Pharma. (DEST) Top Chat Posts

Destiny Pharma. Daily Update: Destiny Pharma. is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DEST. The last closing price for Destiny Pharma. was 67.50p.
Destiny Pharma. has a 4 week average price of 66.50p and a 12 week average price of 66.50p.
The 1 year high share price is 169.25p while the 1 year low share price is currently 66.50p.
There are currently 43,562,598 shares in issue and the average daily traded volume is 13,458 shares. The market capitalisation of Destiny Pharma. is £28,969,127.67.
edmonda: new analysis on pipeline's development and expansion, with increased fair value as a result (a multiple of current share price). Plenty of news expected in coming weeks, too. Note freely accessible here:
jonwig: At the risk of being a boor, I'll repeat my post #7 from four weeks ago: I saw the initial RNS and looked at the website. Basically their compounds appear to act so quickly that bacteria have no time to develop resistance via mutation. My immediate reaction to this was extreme scepticism. It appears to suggest that antibiotic resistant mutations happen when bacteria are stimulated by exposure to an agent. But this isn't the case: they happen purely randomly. Indeed there will already exist resistant strains, and resistant populations will develop and increase by natural selection as happens with current antibiotics. I met a biochemist last week (on holiday) whose discipline is immunology, so not quite the same, and he confirmed that my general understanding was correct. Obviously I need to do more study on this and it would be good to see if the company's research has been peer-reviewed. (A lot of these companies don't allow that.) I know their early trials have been successful, and I may be off-beam here, but I wouldn't want to invest in anything I didn't understand. I just can't find any corroborative information about their compounds (Help anyone?), and first results should be some time away. (How much?) Until then, it's unlikely the share price will do more than respond to speculative froth. A trigger will be phase results, and it's unlikely these can leak as they should be double-blind and reported immediately. When they are, how many here will understand them? More to the point, they seem to have £14m cash with a burn of £2m pa (but that will increase). At least they won't have to scramble.
Destiny Pharma. share price data is direct from the London Stock Exchange
Your Recent History
Destiny Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181218 17:27:35